VivoSim presents liver toxicity data at European toxicology conference

VivoSim Labs, Inc. (Nasdaq: VIVS) announced that data from its 3D human tissue models will be featured in two presentations at the European Society of Toxicology's annual conference, taking place June 29 through July 2, 2026, in Maastricht, the Netherlands.

According to the company's press release, VivoSim's NAMkind™ Liver model achieved 91% predictive accuracy when benchmarked against a clinical dataset of 92 small-molecule compounds, with 90% sensitivity, 95% specificity, and 99% precision under repeat-dose conditions. The company states that traditional animal models and conventional methods provide 50–65% sensitivity for the same compounds, while its models produce fewer than 5% false positives compared to more than 10% for current methodologies.

The presentations also cover VivoSim's NAMkind™ GI intestinal model, which the company says successfully identified distinct mechanistic classes of tyrosine kinase inhibitor-induced diarrhea. Both platforms were also applied to antibody-drug conjugates (ADCs), differentiating hepatic and gastrointestinal risk based on structural properties such as linker stability and payload permeability.

"With a heavy push from the US FDA, the pharmaceutical industry is moving away from traditional animal testing toward high-fidelity, human-relevant alternatives," said Keith Murphy, VivoSim's Executive Chairman. "When a pharma has a miss, the cost to them is many lost years and $50M - $200M."

Chief Scientific Officer Amar Sethi, MD, PhD, said the models allow developers to move "from detecting liabilities to predicting risk," adding that multi-endpoint profiling provides "translational signatures they need to retire toxic liabilities long before a single patient is dosed."

The data are being presented at The 23rd International Congress of the European Society of Toxicology In Vitro (ESTIV 2026). VivoSim, based in San Diego, California, provides preclinical drug testing services using liver and intestinal tissue models.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Five Below reports cybersecurity breach via social engineering
• Intel, Amd Sign Long-term Server Cpu Deals With Chinese Buyers- Reuters